Does Bromelain-Cisplatin Combination Afford In-Vitro Synergistic Anticancer Effects on Human Prostatic Carcinoma Cell Line, PC3?

Fatemeh Amini Chermahini; Elham Raeisi; Mathias Hossain Aazami; Abbas Mirzaei; Esfandiar Heidarian; Yves Lemoigne

doi:10.31661/gmj.v9i0.1749

Does Bromelain-Cisplatin Combination Afford In-Vitro Synergistic Anticancer Effects on Human Prostatic Carcinoma Cell Line, PC3?

Galen Med J. 2020 Aug 29:9:e1749. doi: 10.31661/gmj.v9i0.1749. eCollection 2020.

Authors

Fatemeh Amini Chermahini¹, Elham Raeisi^{2

3}, Mathias Hossain Aazami⁴, Abbas Mirzaei¹, Esfandiar Heidarian³, Yves Lemoigne⁵

Affiliations

¹ Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
² Department of Medical Physics and Radiology, School of Allied Medical Sciences, Shahrekord University of Medical Sciences, Shahrekord, Iran.
³ Clinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
⁴ Department of Cardiology and Cardiac Surgery, Kashani and Hajar University Hospitals, School of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran.
⁵ Department of Medical Physics, Institute for Medical Physics, Ambilly, France.

Abstract

Background: Bromelain enhances anticancer impacts to chemotherapeutic agents. The question as to whether bromelain does promote in-vitro cytotoxic and proapoptotic effects of cisplatin on human prostatic carcinoma PC3 cell line was investigated.

Materials and methods: PC3 (human prostatic carcinoma) cells were treated either single or in combination with bromelain and/or cisplatin. MTT, clonogenic assay, flow cytometry and real-time quantitative polymerase chain reaction were used to investigate cell viability, colony formation, proapoptotic potential and p53 gene expression, respectively.

Results: Cisplatin (IC₁₀) combined with bromelain (IC₄₀) significantly affected PC3 cell viability, inhibited colony formation, as well increased p53 proapoptotic gene expression compared to cisplatin single treatment. Nevertheless, bromelain-cisplatin chemoherbal combination did not display any additive proapoptotic effect compared to single treatments.

Conclusion: Bromelain-cisplatin chemoherbal combination demonstrated synergistic in-vitro anticancer effect on human prostatic carcinoma cell line, PC3, that drastically reduced required cisplatin dose.

Keywords: Bromelain; Cisplatin; Clonogenic Cell Assay; PC3 Cells; Synergistic Effect; p53 Gene.